Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dial eyes aquisitions

This article was originally published in The Tan Sheet

Executive Summary

Firm looking to expand by purchasing new brand for its personal cleaning or household products divisions, CEO Herb Baum states at Banc of America securities Health Conference in San Francisco Sept. 16. Any acquisition "has to have an 18% or higher operating margin" to fit in company's current distribution system, exec notes, adding "we're good at liquid in a bottle." Baum also says international expansion is on hold after prior management team's ill-fated efforts in Argentina (1"The Tan Sheet," February 10, 2003, p. 10). "We're going to stay close to home...[as] there is a lot of growth left in North America," he asserts. Company is "comfortable" with third quarter and full-year guidance of $0.34 and $1.33 earning per share, respectively...

You may also be interested in...



Sales & Earnings In Brief

Bausch & Lomb: Worldwide lens care sales rose 8% to $121 mil. in Q4, led by ReNu products' double-digit gains in the Americas and Asia, according to Jan. 30 1company announcement. For the year, lens care revenues advanced 12% to $465.5 mil. Positive lens care performance, along with similar strong gains in contact lens and pharmaceuticals sales, helped power 9% overall sales increase to $1.81 bil. in 2002 versus the previous year, firm reports; full year net earnings rose to $72.5 mil. in 2002 from $21.2 mil. a year ago. B&L expects "low single-digit growth in" lens care sales in 2003. Additionally, Chairman & CEO Ronald Zarrella will oversee firm's Americas region commercial business until a successor is named for B&L exec Mark Sieczkarek, who left Jan. 31 "to pursue career opportunities elsewhere"...

IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Topics

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel